BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)
- First Posted Date
- 2018-03-06
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 552
- Registration Number
- NCT03455439
- Locations
- 🇪🇸
Many Locations, Multiple Locations, Spain
A Study to Assess Menstrual Cramp Pain Associated With Primary Dysmenorrhea
Phase 4
Completed
- Conditions
- Dysmenorrhea
- Interventions
- First Posted Date
- 2018-02-28
- Last Posted Date
- 2019-10-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 201
- Registration Number
- NCT03448536
- Locations
- 🇺🇸
Synexus US, LP- Plano, Plano, Texas, United States
🇺🇸Radiant Research, Inc., Dallas, Texas, United States
A Study to Evaluate Changes in Nasal Airflow of Loratadine/Pseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure
Phase 4
Completed
- Conditions
- Rhinitis, Allergic
- Interventions
- Drug: Placebo tabletDrug: Placebo spray
- First Posted Date
- 2018-02-23
- Last Posted Date
- 2019-12-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 82
- Registration Number
- NCT03443843
- Locations
- 🇨🇦
Kingston General Hospital, Kingston, Ontario, Canada
In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control
Not Applicable
Completed
- Conditions
- Atopic Dermatitis
- Interventions
- Device: Modified Diprobase formulation (BAY987534)
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2020-07-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 40
- Registration Number
- NCT03441568
- Locations
- 🇬🇧
West Timperley Medical Centre, Altrincham, United Kingdom
BAY2328065 Single Dose Escalation, Safety and Tolerability, Pharmacokinetics, Relative Bioavailability, Food Effect
- First Posted Date
- 2018-02-09
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 72
- Registration Number
- NCT03427788
- Locations
- 🇩🇪
CRS Clinical Research Services Berlin GmbH, Berlin, Germany
A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects Under Fed Conditions
Phase 1
Completed
- Conditions
- Clinical Pharmacology
- Interventions
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 60
- Registration Number
- NCT03424135
- Locations
- 🇺🇸
ICON Development Solutions, LLC, San Antonio, Texas, United States
Multi-academic Center Study of Xofigo Patients
Completed
- Conditions
- Prostate Cancer, Castration Resistant
- Interventions
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 150
- Registration Number
- NCT03419442
- Locations
- 🇺🇸
Bayer US, Whippany, New Jersey, United States
A Study of Molidustat for Treatment of Renal Anemia in Peritoneal Dialysis Subjects
Phase 3
Completed
- Conditions
- AnemiaRenal Insufficiency, Chronic
- Interventions
- First Posted Date
- 2018-02-01
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 51
- Registration Number
- NCT03418168
- Locations
- 🇯🇵
Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan
🇯🇵Fukushima Medical University Hospital, Fukushima, Japan
🇯🇵Asahi University Hospital, Gifu, Japan
Evaluate the Effectiveness of Intravitreal (IVT) Aflibercept Injection in Clinical Practice in naïve Patients With Neovascular Age-related Macular Degeneration (nAMD)
Completed
- Conditions
- Macular Degeneration
- Interventions
- First Posted Date
- 2018-01-26
- Last Posted Date
- 2019-12-05
- Lead Sponsor
- Bayer
- Target Recruit Count
- 116
- Registration Number
- NCT03411941
- Locations
- 🇪🇸
Many locations, Multiple Locations, Spain
A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY1142524 in Patients With Type II Diabetes and a Clinical Diagnosis of Diabetic Kidney Disease
Phase 2
Completed
- Conditions
- Diabetic Kidney Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-01-26
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- Bayer
- Target Recruit Count
- 152
- Registration Number
- NCT03412006
- Locations
- 🇧🇬
Med. Center Equita, Varna, Bulgaria
🇫🇮TAYS TKI Keskus Tutkimusvastaanotto, Tampere, Finland
🇮🇱The Nazareth Trust Hospital EMMS, Nazareth, Israel
© Copyright 2025. All Rights Reserved by MedPath